Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND MUC16, CA125, CA-125 AND Staging
19 results:

  • 1. Construction and validation of artificial intelligence pathomics models for predicting pathological staging in colorectal cancer: Using multimodal data and clinical variables.
    Tan Y; Liu R; Xue JW; Feng Z
    Cancer Med; 2024 Apr; 13(7):e6947. PubMed ID: 38545828
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer.
    Cengiz A; Yersal Ö; Ömürlü İK; Yürekli Y
    Indian J Cancer; 2023; 60(2):224-229. PubMed ID: 37530245
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tumour genotypes account for survival differences in right- and left-sided colon cancers.
    Ward TM; Cauley CE; Stafford CE; Goldstone RN; Bordeianou LG; Kunitake H; Berger DL; Ricciardi R
    Colorectal Dis; 2022 May; 24(5):601-610. PubMed ID: 35142008
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. BH-index: A predictive system based on serum biomarkers and ensemble learning for early colorectal cancer diagnosis in mass screening.
    Battista A; Battista RA; Battista F; Iovane G; Landi RE
    Comput Methods Programs Biomed; 2021 Nov; 212():106494. PubMed ID: 34740064
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. High-risk Stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironment.
    Ge W; Hu H; Cai W; Xu J; Hu W; Weng X; Qin X; Huang Y; Han W; Hu Y; Yu J; Zhang W; Ye S; Qi L; Huang P; Chen L; Ding K; Wang LD; Zheng S
    Int J Cancer; 2020 Apr; 146(7):2027-2035. PubMed ID: 31693169
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Clinicopathological characteristics of type 2 diabetes mellitus complicated with colorectal cancer].
    Han ZH; Chen JJ; Feng N; Niu PF; Song C; Gao ZY; Gao QK; Ji DB; Wang WB; Lei FM; Gu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):966-971. PubMed ID: 31630495
    [No Abstract]    [Full Text] [Related]  

  • 7. [Correlation of ¹⁸F-FDG PET-CT maximum standard uptake value and T/N ratio with the prognosis of postoperative colorectal cancer].
    Wang X; Peng G; Zhang X; Chen Z; Zhang B; Li Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):232-7. PubMed ID: 25809325
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Recent progress in the diagnosis and treatment of ovarian cancer.
    Jelovac D; Armstrong DK
    CA Cancer J Clin; 2011; 61(3):183-203. PubMed ID: 21521830
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
    Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
    Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
    Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Application of urinary nucleosides in the diagnosis and surgical monitoring of colorectal cancer].
    Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Yu BM
    Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):564-8. PubMed ID: 15938925
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Gastrointestinal cancer].
    Takahashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
    Martell RE; Xu FJ; Davis WZ; Anselmino L; Yu YH; Daly L; Bast RC
    Int J Biol Markers; 1998; 13(3):145-9. PubMed ID: 10079388
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Current status of staging laparotomy in colorectal and ovarian cancer.
    Boente MP; Yeh K; Hogan WM; Ozols RF
    Cancer Treat Res; 1996; 82():337-57. PubMed ID: 8849961
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Application of whole layer core biopsy of bladder wall to paravesical tumor].
    Hoshi S; Orikasa S; Suzuki K; Kaneda T; Konda R; Maehara I; Kato H
    Hinyokika Kiyo; 1994 Nov; 40(11):981-5. PubMed ID: 7832084
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Tumor markers, liver function tests and symptoms in 115 patients with isolated colorectal liver metastases.
    Lorenz M; Baum RP; Oremek G; Inglis R; Reimann-Kirkowa M; Hör G; Seiffert U; Hottenrott C
    Int J Biol Markers; 1989; 4(1):18-26. PubMed ID: 2746045
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19-9 and CA 125.
    Baum RP; Lorenz M; Hottenrott C; Albrecht M; Senekowitsch R; Happ J; Hertel A; Spitz J; Hör G
    Int J Biol Markers; 1988; 3(3):177-84. PubMed ID: 3230337
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
    Szymendera JJ
    Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.